At Jeevan Therapeutics, we are pioneering precision medicines for colon-associated diseases with a differentiated approach to disease relapse and resistance. Over the past few months, we’ve achieved several key milestones — securing strategic funding, advancing our pipeline, expanding partnerships, and strengthening our scientific leadership — positioning Jeevan for an exciting next chapter.
Strategic Milestones
- Financing Progress: Earlier this year, we secured strategic funding from Imbolc Partners and, most recently, additional financing from a family office, strengthening our runway and enabling key near-term development milestones. We are in active discussions with several early-stage life sciences investors and foundations regarding additional funding as the Abkyu collaboration reaches key milestones in Q4 25 and Q1 26.
- Abkyu Partnership: We established a collaboration with Abkyu (link to our press release) to accelerate the discovery of next-generation antibodies using their advanced VHH discovery platform — supporting the rapid development of our JTx-ADC program for immune-mediated diseases.
- Pipeline Momentum:
- Our JTx-ADC program is prioritized for Crohn’s disease, leveraging novel insights into CRM (Cellular Mediators of Relapse) biology to address disease recurrence and improve durable remission rates.
- In parallel, our abCAT small-molecule program is strategically positioned to exploit synthetic lethality in Gene-JTx-driven colorectal cancers, targeting a significant unmet need.
- Scientific Advisory Board (SAB): We’ve established Jeevan’s first SAB, chaired by our CSO, Dr. Dinesh Chimmanamada, with the addition of Dr. Mehmet Ozturk, a renowned expert in oncology, antibodies, and ADC-related science, as a founding member.
- Team Expansion: We are thrilled to welcome Dr. Eric Haines, an experienced biologist, who brings deep expertise in translational science and preclinical development to accelerate our pipeline. Dr. Haines joins us with extensive leadership roles across discovery and development at Ikena Oncology, Bicycle Therapeutics, and Corbus Pharmaceuticals, along with postdoctoral research experience at Dana-Farber and EMD Serono.
Scientific Highlights
Our approach targets the root causes of disease recurrence and resistance:
- Our JTx-ADC program is designed to selectively deplete cellular mediators of relapse (CRM) in Crohn’s disease, addressing the drivers of persistent inflammation and improving durable remission rates.
- In parallel, our abCAT program exploits synthetic lethality to target colorectal cancers driven by Gene-JTx, enabling a differentiated approach where current treatments fall short.
Looking Ahead
We are entering a period of rapid progress and key value inflection points:
- Lead JTx-ADC candidate nomination targeted for Q1 2026
- IND-enabling studies expected to follow, with first-in-human studies anticipated in 1H 2028 (timelines subject to refinement as programs advance)
- Continued expansion of strategic partnerships and collaborations
Upcoming Conferences
We are attending the following conferences and would be happy to connect:
- LSX World Congress – Boston – September 16-17
- MassBIO Align Summit – Boston – October 7
At Jeevan, we are driven by our mission to redefine the standard of care for patients with colon-associated diseases. We’re excited to share this journey with you and look forward to keeping you updated as we continue to advance our programs.